InspireMD (NYSE:NSPR) Shares Down 1.8% – Here’s What Happened

InspireMD, Inc. (NYSE:NSPR)’s share price traded down 1.8% during trading on Thursday . The company traded as low as $1.6001 and last traded at $1.62. 17,462 shares traded hands during trading, a decline of 52% from the average session volume of 36,529 shares. The stock had previously closed at $1.65.

InspireMD Trading Down 1.8%

The business’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $2.17. The company has a market capitalization of $68.64 million, a PE ratio of -2.16 and a beta of 0.72.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Creative Planning acquired a new stake in shares of InspireMD during the 2nd quarter worth approximately $44,000. Uniting Wealth Partners LLC acquired a new position in shares of InspireMD during the 3rd quarter worth approximately $51,000. Citadel Advisors LLC increased its holdings in InspireMD by 45.0% in the 3rd quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock worth $91,000 after acquiring an additional 11,778 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after purchasing an additional 10,000 shares during the period. Finally, Vestia Personal Wealth Advisors lifted its stake in InspireMD by 135.7% in the 3rd quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock valued at $102,000 after buying an additional 24,425 shares in the last quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.